Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what.
Metman
L V
LV
Konitsiotis
S
S
Chase
T N
TN
D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D003342:Corpus Striatum / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D009048:Motor Skills / Q000187:drug effects / Q000502:physiology*; D009434:Neural Pathways / Q000187:drug effects / Q000503:physiopathology; D009474:Neurons / Q000502:physiology; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects / Q000502:physiology; D017661:Receptors, Presynaptic / Q000187:drug effects / Q000502:physiology; D013378:Substantia Nigra / Q000187:drug effects / Q000503:physiopathology; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D011954:Receptors, Dopamine; D016194:Receptors, N-Methyl-D-Aspartate; D017661:Receptors, Presynaptic; D007980:Levodopa